Revolution Medicines, Inc. reiterated earnings guidance for the full year 2024. The company is reiterating its projected full year 2024 GAAP net loss to be between $480 million and $520 million, which includes estimated non-cash stock-based compensation expense of between $70 million and $80 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.34 USD | +0.47% | +5.24% | +40.66% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.66% | 6.66B | |
+51.85% | 57.87B | |
+41.87% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2024